219 related articles for article (PubMed ID: 22639903)
1. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): moving forward.
Malyguine A; Umansky V; Kotlan B; Aptsiauri N; Shurin MR
J Immunotoxicol; 2012; 9(3):231-5. PubMed ID: 22639903
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy and immunomonitoring (CITIM): redefining cancer therapy.
Malyguine A; Umansky V; Shurin MR
J Immunotoxicol; 2009 Dec; 6(4):205-8. PubMed ID: 19908938
[TBL] [Abstract][Full Text] [Related]
3. Conference Scene: Immunotherapy reaches new milestones in cancer eradication.
Kotlan B; Umansky V; Malyguine AM; Marincola FM; Shurin MR
Immunotherapy; 2011 Oct; 3(10):1131-7. PubMed ID: 21995567
[TBL] [Abstract][Full Text] [Related]
4. From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011.
Umansky V; Malyguine A; Kotlan B; Aptsiauri N; Shurin MR
Cancer Immunol Immunother; 2012 Feb; 61(2):295-301. PubMed ID: 21953053
[No Abstract] [Full Text] [Related]
5. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
6. Redefining cancer immunotherapy-optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27-30, 2015, Ljubljana, Slovenia.
Aptsiauri N; Jewett A; Hurwitz AA; Shurin MR; Umansky V
Cancer Immunol Immunother; 2016 Jul; 65(7):875-83. PubMed ID: 26810566
[No Abstract] [Full Text] [Related]
7. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
9. A fresh look at tumor immunosurveillance and immunotherapy.
Smyth MJ; Godfrey DI; Trapani JA
Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy.
Baxevanis CN; Perez SA; Papamichail M
Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
[TBL] [Abstract][Full Text] [Related]
12. Immune monitoring of cancer patients undergoing experimental immunotherapy.
Shankar G; Salgaller ML
Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
[TBL] [Abstract][Full Text] [Related]
13. Current developments in cancer vaccines and cellular immunotherapy.
Ribas A; Butterfield LH; Glaspy JA; Economou JS
J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
[TBL] [Abstract][Full Text] [Related]
14. Improving the efficacy of cancer immunotherapy.
Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22-25 April 2013, Krakow, Poland.
Shurin MR; Umansky V; Malyguine A; Hurwitz AA; Apte RN; Whiteside T; Jewett A; Thanavala Y; Murphy WJ
Cancer Immunol Immunother; 2014 Jan; 63(1):73-80. PubMed ID: 24271210
[No Abstract] [Full Text] [Related]
16. Dendritic cells in cancer immunotherapy.
Gunzer M; Grabbe S
Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
[TBL] [Abstract][Full Text] [Related]
17. From cancer immunosurveillance to cancer immunotherapy.
Stagg J; Johnstone RW; Smyth MJ
Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
[TBL] [Abstract][Full Text] [Related]
18. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
19. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
20. Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.
Brehm C; Huenecke S; Pfirrmann V; Rossig C; Mackall CL; Bollard CM; Gottschalk S; Schlegel PG; Klingebiel T; Bader P
Pediatr Hematol Oncol; 2013 Aug; 30(5):349-66. PubMed ID: 23758210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
